Adipose-derived mesenchymal stem cells alleviate TNBS-induced colitis in rats by influencing intestinal epithelial cell regeneration, Wnt signaling, and T cell immunity

Figure 2 Tail injection of adipose-derived mesenchymal stem cells in rats protects against TNBS-induced colitis. A: Disease activity index of respective groups from baseline. -1 d indicates the day before adipose-derived mesenchymal stem cell (ADSC) injection, 7 d, 14 d, 21 d, and 28 d represent 7 d, 14 d, 21 d, and 28 d after ADSC therapy, respectively; B: Gross morphology of colon tissue and colon length among the groups; C: Representative hematoxylin and eosin staining of colon tissue in the three groups (scale bar: 100 μm); D: Serum concentrations of anti-sacchromyces cerevisiae antibody and p-antineutrophil cytoplasmic antibody detected by ELISA. Data are presented as the mean ± SD. ^aP < 0.05, ^bP < 0.01 vs control group; ^cP < 0.05, ^dP < 0.01 vs CD group. ADSCs: Adipose-derived mesenchymal stem cells; CD: Crohn’s disease; GFP: Green fluorescent protein.